Analyst Price Targets — ORGO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 7, 2026 2:18 pm | Ravi Misra | Truist Financial | $2.00 | $1.64 | TheFly | Organogenesis price target lowered to $2 from $3 at Truist |
| May 28, 2026 10:13 am | — | UBS | $3.00 | $2.66 | TheFly | Organogenesis initiated with a Hold at Truist |
| May 28, 2026 10:06 am | Ravi Misra | Truist Financial | $3.00 | $2.66 | StreetInsider | Truist Securities Starts Oranogenesis Holdings (ORGO) at Hold |
| November 20, 2025 12:10 pm | — | BTIG | $9.00 | $5.14 | TheFly | Organogenesis price target raised to $9 from $7 at BTIG |
| March 5, 2025 12:21 pm | — | Morgan Stanley | $6.00 | $6.01 | TheFly | Organogenesis price target raised to $6 from $4 at Morgan Stanley |
| June 28, 2024 8:01 am | Brooks O'Neil | Lake Street | $5.00 | $2.64 | TheFly | Organogenesis initiated with a Buy at Lake Street |
Latest News for ORGO
Organogenesis NASDAQ: ORGO reported a sharp year-over-year decline in second-quarter revenue as the skin substitute market continued to adjust to coverage and payment changes from the Centers for Medicare & Medicaid Services, while management pointed to sequential improvement in product sales and market share gains.
Organogenesis Holdings Inc. (ORGO) Q2 2026 Earnings Call Transcript
CANTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacture, and sale of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the second quarter ended June 30, 2026.
CANTON, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced published results from a prospective, multicenter, randomized controlled trial (RCT) evaluating Affinity plus standard of care (SoC) compared to SoC alone in the…
CANTON, Mass., July 09, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care, and surgical and sports medicine markets, today announced that second quarter of fiscal year 2026 financial results will be reported after the…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ORGO.
U.S. House Trading
No House trades found for ORGO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.